VIENNA, AustriaProof that starting adjuvant goserelin (Zoladex)
treatment simultaneously with radiotherapy improves local control and
survival in men with locally advanced prostate cancer emerged 2 years
ago from a study conducted jointly by the Radiotherapy and
Genitourinary groups of the European Organization for Research and
Treatment of Cancer (EORTC).
Now, the latest update from that phase III study indicates that the
survival edge conferred by the combined modality approach is
maintained for at least 5½ years of follow-up.
The EORTC investigators randomized 415 patients with T1-T2 grade 3
prostate adenocarcinoma or T3-T4 prostate adenocarcinoma of any grade
to receive radiotherapy (50 Gy over 5 weeks followed by a 20 Gy boost
over 2 weeks) alone or in combination with the LHRH analog goserelin
(3.6 mg injected subcutaneously on the first day of radiation and
every 4 weeks thereafter for 3 years).
At the 10th European Cancer Conference (ECCO 10), Michel Bolla, MD,
of University Hospital, Grenoble (France), reported that, after a
median follow-up period of 65.7 months, overall survival remained
significantly better in patients who received radiotherapy and
hormonal therapy than in those treated with radiotherapy alone (78%
vs 62%, P < .001).
Significant benefits in favor of adjuvant goserelin treatment were
likewise apparent for disease-specific survival (94% vs 79%, P <
.001); biochemically defined disease-free survival (76% vs 45%, P <
.001); and clinically defined disease-free survival (74% vs 37%,
P < .001), Dr. Bolla said. Combined treatment also significantly
delayed the time to first clinical failure and the time to